List view / Grid view

Drug delivery

 

Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline

3 November 2014 | By Auspherix Pty Ltd

Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further with AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies...

Particle characterisation in drug delivery

5 September 2014 | By Driton Vllasaliu and Ishwar Singh, University of Lincoln

The use of materials in nano-scale dimensions is proving to be a promising approach to overcome drug delivery challenges. ‘Nanomedicine’ technologies are gradually achieving commercial success and reaching the clinic. Sub-micron nanocarriers have the potential to ferry the therapeutic to its site of action and in this process overcome the…

Merck announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet

5 March 2014 | By

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…

Send this to a friend